Jagsonpal Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹81 Cr +9.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
JP

Jagsonpal Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Jagsonpal Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹64Cr
+8.5% YoY
−12.3% QoQ
Net profit
₹9Cr
+28.6% YoY
−18.2% QoQ
Margin
17%
+2 pp YoY
−5 pp QoQ
Price₹237
Market cap₹1.5K Cr
P/E31.8

The short version

Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.

From Jagsonpal Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth.
  • Volume growth for FY26 was 2% for Jagsonpal, slightly higher than the market's ~1%.
  • New product launches contribute around 3.2% to growth, matching or exceeding industry averages.
  • Price growth is around 6%-7%, which is higher than the IPM price growth (~4.8%-5%).
  • Focus on strong therapeutic areas: Gynaecology (about 50% of business), Orthopedics (~25%), and Dermatology (10%-15%), with growth led mainly by Gynaec and Derma.
  • Enhancing MR productivity and training to increase sales efficiency without increasing headcount.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.
  • Current capital expenditure is focused on maintaining existing operations and organic business growth.
  • Any capital deployment of real cash will be primarily for inorganic strategies, such as acquisitions.
  • The company has adequate cash (~INR190 crores) and access to bank finance, making it capable of funding acquisitions up to INR400 crores without stressing the balance sheet.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Jagsonpal Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jagsonpal Pharmaceuticals Ltd Q4 FY26 results — key figures

Jagsonpal Pharmaceuticals Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue6459+8.5%73-12.3%
Operating profit (EBITDA)119+22.2%16-31.2%
Operating margin17%15%+2 pp22%-5 pp
Profit before tax129+33.3%15-20%
Net profit (PAT)97+28.6%11-18.2%
EPS (₹)1.310.99+32.3%1.64-20.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jagsonpal Pharmaceuticals Ltd Q4 FY26 results?

Jagsonpal Pharmaceuticals targets organic growth at approximately 1.5x the Indian Pharma Market (IPM) growth, aiming for 12%-15% revenue growth. Jagsonpal aims to sustain and accelerate growth momentum, targeting 1.5x the Indian Pharma Market (IPM) growth (currently 6%-9%), implying 12%-15% revenue growth.

What is Jagsonpal Pharmaceuticals Ltd share price analysis?

Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?

Jagsonpal Pharmaceuticals Limited does not require additional capital for organic growth, as growth is driven by better execution and field force productivity rather than capital-intensive investments.

Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.